After chiming in antibody to Covid-19 fight, Junshi drops $30M to kick off mRNA joint venture in China

A pioneering biotech in China has its eyes on mRNA.

Junshi Biosciences — which made its name as the first domestic drugmaker to steer a PD-(L)1 across the finish line at the NMPA — is teaming up with fellow Shanghai biotech Immorna on a joint venture that will be dedicated...

Click to view original post